PTK2 and Miyoshi myopathy: Strikingly, FAK inhibition also re-sensitized therapy-resistant MM cells, isolated from three mutBRAF (M45, M53, M59) and three mutNRAS (M10, M20, M32) metastasis relapsed from targeted kinase-inhibition.